Clinical trials: Metabolic Evaluation
Homozygous Familial Hypercholesterolemia
Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
A multicenter, single arm, open label phase II clinical study evaluating the long-term efficacy and safety of SHR-1918 in homozygous familial hypercholesterolemia patients
- Trial name
- NCT07133815
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Overweight
Efficacy and Safety of Zenoctil in Reducing Body Weight
The intention of the study is to evaluate the safety and potential body weight and body fat loss effects of a 12-week treatment with Zenoctil in a randomized, double-blind, placebo-controlled, parallel study conducted in…
- Trial name
- NCT01423617
- Testing
- Zenoctil
- Where
- Germany
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Fabry Disease
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat)…
- Trial name
- CARAT (NCT05280548)
- Testing
- Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828)
- Where
- 54 sites in United States, Austria and 17 more
- Volunteers
- 104 people
- Sponsor
- Sanofi
Type 2 Diabetes
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese subjects.
- Trial name
- NCT03645421
- Testing
- MEDI0382 100 μg, MEDI0382 200 μg, MEDI0382 300 μg
- Where
- 5 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
A Clinical Study of the C8 MediSensors Optical Glucose Monitor™
The purpose of this study is to compare glucose measurements from the C8 MediSensors non-invasive Optical Glucose Monitor™ System to blood glucose measurements from the Yellow Springs Instrument(YSI) blood glucose analyzer.
- Trial name
- Spectrum (NCT01726114)
- Testing
- Non-invasive Optical Glucose Monitor™, YSI blood glucose analyzer
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- C8 MediSensors, Inc.
Type 2 Diabetes
Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes
The planned study is to evaluate the efficacy, safety and pharmacokinetic (PK) properties of CPL207280 after multiple (14 days) administration in patients with type 2 diabetes.
- Trial name
- NCT05248776
- Testing
- CPL207280
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Celon Pharma SA
Painful Diabetic Peripheral Neuropathy (PDPN)
Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy
A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy…
- Trial name
- ENFORCE (NCT06715462)
- Testing
- N0750, Cymbalta®, Lyrica®
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Osteopenia
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of…
- Trial name
- NCT00950950
- Testing
- Romosozumab
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide…
- Trial name
- NCT07755150
- Testing
- DA-302168S
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Type 2 Diabetes Mellitus and Microalbuminuria
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind…
- Trial name
- NCT02332824
- Testing
- TAK-272, Candesartan cilexetil
- Where
- 68 sites in Japan
- Volunteers
- 415 people
- Sponsor
- Takeda
Disorder of Circulatory System, Metabolic Disease
Investigation of Long-term Effects of CarelessTM on Microcirculation
Aim of the study is to investigate long-term effects of CarelessTM, a Mangifera indica fruit powder on microcirculation and endothelial function after supplementation of 4 weeks.
- Trial name
- NCT02588313
- Testing
- Mango fruit powder
- Where
- Germany
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Vital Solutions Swiss AG
Diabetes Mellitus, Type 2, Renal Disease
A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases
- Conditions
- Diabetes Mellitus, Type 2, Renal Disease, Diabetes Mellitus, Metabolic Disease
- Trial name
- NCT04653779
- Testing
- Evogliptin 5mg/Metformin 1000mg
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Dong-A ST Co., Ltd.
Hyperlipidemia
Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia
The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.
- Trial name
- NCT00810979
- Testing
- SLx-4090, Statin
- Where
- 19 sites in United States
- Volunteers
- 133 people
- Sponsor
- Response Pharmaceuticals
Type 2 Diabetes, Obesity
Balance System Study in Type 2 Diabetic Patients
To evaluate the safety and performance of the BALANCE System in treating patients who have type 2 diabetes and are overweight. Impact on blood glucose levels, weight loss, blood pressure and other clinical and metabolic…
- Trial name
- NCT00872846
- Testing
- BALANCE System intestinal electrical stimulator
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Beta-Stim Ltd.
Overweight and Obesity
The Food Effect on Pharmacokinetics of DA-302168S
This study will be conducted to determine the effect of food on the pharmacokinetics characteristic of DA-302168S following administration of a DA-302168S tablet with and without a high-fat meal.
- Trial name
- DA168 (NCT06534346)
- Testing
- 15 mg DA-302168S tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Type 2 Diabetes
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
This is a non-inferiority study comparing omarigliptin with sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy.
- Trial name
- NCT01841697
- Testing
- Omarigliptin, Sitagliptin, Open-label Metformin
- Volunteers
- 642 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Overweight or Obesity
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo.
- Trial name
- VESPER-3 (NCT06973720)
- Testing
- MET097
- Where
- 5 sites in United States
- Volunteers
- 268 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 1
The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins
This trial is conducted in Europe. The aim of this research is to assess the impact of three basal (long-acting) insulin treatments on blood glucose levels in people with type 1 diabetes when performing physical exercise.
- Trial name
- NCT00313742
- Testing
- insulin detemir, insulin glargine, insulin NPH
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Novo Nordisk A/S
Congenital Adrenal Hyperplasia
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic Congenital adrenal hyperplasia (CAH) subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
- Trial name
- NCT04544410
- Where
- 43 sites in United States, Australia and 14 more
- Volunteers
- 100 people
- Sponsor
- Spruce Biosciences
Gout, Hyperuricemia
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in…
- Trial name
- NCT04139824
- Testing
- Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Chem
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.